Assignee
XTL BIOPHARMACEUTICALS LTD
IL·6 granted patents·4 pending applications·54 citations·filing 1997–2020
Top patents by PatentIndex Score
10 records- 0173US6146629AHuman monoclonal antibody against Hepatitis B virus surface antigen (HBVsAg)XTL BIOPHARMACEUTICALS LTD·Filed 1997·Granted Nov 14, 2000·33 cites·11 claims
- 0271USRE39586EHuman monoclonal antibody against Hepatitis B virus surface antigen (HBVSAG)XTL BIOPHARMACEUTICALS LTD·Filed 1997·Granted Apr 24, 2007·21 cites·12 claims
- 0358US2020338195A1Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosusXTL BIOPHARMACEUTICALS LTD·Filed 2020·Application pending·0 cites
- 0452US7994360B2Benzofuran compoundsXTL BIOPHARMACEUTICALS LTD·Filed 2005·Granted Aug 9, 2011·0 cites·1 claims
- 0550US2018043016A1Pharmaceutical compositions comprising 0.25 mg dose of synthetic human peptides for treating systemic lupus erythematosusXTL BIOPHARMACEUTICALS LTD·Filed 2017·Application pending·0 cites
- 0647US8048889B23,4-disubstituted coumarin and quinolone compoundsXTL BIOPHARMACEUTICALS LTD·Filed 2005·Granted Nov 1, 2011·0 cites·12 claims
- 0746US7923004B24-ethynyl pyrazole derivative compounds and methods for treatment of HCVXTL BIOPHARMACEUTICALS LTD·Filed 2007·Granted Apr 12, 2011·0 cites·13 claims
- 0844US2018043017A1Pharmaceutical compositions comprising 0.5 mg dose of synthetic human peptides for treating systemic lupus erythematosusXTL BIOPHARMACEUTICALS LTD·Filed 2017·Application pending·0 cites
- 0942US7148253B24-thio coumarinsXTL BIOPHARMACEUTICALS LTD·Filed 2004·Granted Dec 12, 2006·0 cites·31 claims
- 1035US2005260195A1Treatment of hepatitis B virus infection with human monoclonal antibodiesXTL BIOPHARMACEUTICALS LTD·Filed 2005·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when XTL BIOPHARMACEUTICALS LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →